| CAS NO. |
Products Name |
| 152121-30-7 |
SB202190 |
more... |
| SB202190 (FHPI) is a potent p38 MAPK inhibitor targeting p38α/β with IC50 of 50 nM/100 nM, sometimes used instead of SB 203580 to investigate potential roles for SAPK2a/p38 in vivo. |
|
| 305350-87-2 |
SL327 |
more... |
| SL327 is a selective inhibitor for MEK1/2 with IC50 of 0.18 μM/ 0.22 μM, no activity towards Erk1, MKK3, MKK4, c-JUN, PKC, PKA, or CamKII;capable of transport through the blood-brain barrier. |
|
| 285983-48-4 |
BIRB 796 (Doramapimod) |
more... |
| BIRB 796 (Doramapimod) is a highly selective p38α MAPK inhibitor with Kd of 0.1 nM, 330-fold greater selectivity versus JNK2, weak inhibition for c-RAF, Fyn and Lck, insignificant inhibition of ERK-1, SYK, IKK2, ZAP-70, EGFR, HER2, PKA, PKC, PKCα/β/γ. |
|
| 391210-10-9 |
PD0325901 |
more... |
| PD0325901 (PD325901) is selective and non ATP-competitive MEK inhibitor with IC50 of 0.33 nM, roughly 500-fold more potent than CI-1040 on phosphorylation of ERK1 and ERK2. Phase 2. |
|
| 167869-21-8 |
PD98059 |
more... |
| PD98059 is a non-ATP competitive MEK inhibitor with IC50 of 2 μM, specifically inhibits MEK-1-mediated activation of MAPK; does not directly inhibit ERK1 or ERK2. |
|
| 745833-23-2 |
VX-702 |
more... |
| VX-702 is a highly selective inhibitor of p38α MAPK, 14-fold higher potency against the p38α versus p38β. Phase 2. |
|
| 391210-00-7 |
PD318088 |
more... |
| PD318088 is a non-ATP competitive allosteric MEK1/2 inhibitor, binds simultaneously with ATP in a region of the MEK1 active site that is adjacent to the ATP-binding site. |
|
| 585543-15-3 |
Losmapimod(SB56553) |
more... |
| Losmapimod (GW856553X; SB856553; GSK-AHAB) is a selective, potent, and orally active p38 MAPK inhibitor with pKi of 8.1 and 7.6 for p38α and p38β, respectively. |
|
|
|
| 1168091-68-6 |
GDC-0623 |
more... |
| GDC-0623 is a potent, ATP-uncompetitive inhibitors of MEK1(Ki=0.13 nM, +ATP); 6-fold weaker potency against HCT116 (KRAS(G13D), EC50=42 nM) versus A375 (BRAF(V600E), EC50=7 nM). |
|
| 212631-79-3 |
PD184352 |
more... |
| CI-1040 is a selective MEK inhibitor (Ki = 300 nM in vitro). CI-1040 suppresses FGF-mediated angiogenesis in vivo and decreases VEGF expression. Enhances the therapeutic efficacy of taxol in vivo. Orally active. |
|
| 72873-74-6 |
SKF-86002 |
more... |
| SKF-86002 is a potent inhibitor of p38 MAP kinase wit IC50 of 0.5-1 uM; inhibits LPS-induced IL-1 and TNF-α production in human monocytes (IC50 = 1 μM). |
|
All Products
